Atossa Therapeutics Inc Sustainability Reports
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines in areas of oncology and breast health. Its lead drug candidate is oral (Z)-endoxifen, currently under phase 2 development for the treatment and reduction of breast cancer risk.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300QRKP1JTNHD2366
FIGI: BBG002NCD954
2 reports from 2023 to 2025
